[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cognitive-deficit\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cognitive-deficit":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,44,78,100,129,165],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100500932","neurocognitive-effects-of-non-invasive-near-infrared-light-stimulation-100500932",false,"NCT05802680","Neurocognitive Effects of Non-Invasive Near-Infrared Light Stimulation","Inclusion Criteria:\n\n* 18 years of age or older\n\nExclusion Criteria:\n\n* None",true,"ALL","18 Years",{"count":19,"type":20},500,"ESTIMATED","INTERVENTIONAL",[23],"NA","Inattentiveness and impulsivity in healthy adults and individuals with attention deficit hyperactivity disorder (ADHD) diminish these individuals' quality of life. Cortical hypometabolism has been hypothesized to contribute to inattentiveness in ADHD. Transcranial photobiomodulation (tPBM) is a safe and non-invasive modality for activation of the prefrontal cortex. tPBM in healthy adults has been shown to augment brain oxygenation, cognition, and mood. The cognition-enhancing effect of tPBM on sustained attention in adults with ADHD remains unstudied. The investigators will evaluate whether tPBM administration to adults with and without ADHD can improve their attention. Each participant will be screened for eighteen criteria based on the Diagnostic and Statistical Manual (DSM-IV, text revised), using the validated instrument Adult ADHD Self-Report Scale (ASRS-v1.1). Blinded participants will be randomized into (I) Active-tPBM or (II) Sham-tPBM groups. After undergoing an 8-minute administration of Sham or 1064 nm tPBM to the lateral and medial right prefrontal cortex, each participant will complete a 14-minute, computer-based Conner's continuous performance task-3 (CPT-3). The investigators will examine whether adults with and without ADHD who receive Active-tPBM improve in measures of inattention, impulsivity, sustained attention, or vigilance compared to the Sham-tPBM group. Cognitive assessments of attention like the CPT-3 may evaluate the efficacy of tPBM to increase cortical metabolism in healthy adults and individuals with conditions like ADHD. The investigators anticipate their investigation will be a starting point for more sophisticated studies that focus on the implications of tPBM on cognition.",[26,27,28,29,30],"Attention Deficit Hyperactivity Disorder","Attention Difficulties","Attention Deficit","Cognitive Deficit","Wellness","RECRUITING","2026-06-17",{"date":34,"type":35},"2026-06-22","ACTUAL",{"date":37,"type":35},"2022-02-09",{"date":39,"type":20},"2027-02-01",{"name":41,"class":42},"Francisco Gonzalez-Lima, PhD","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":55,"conditions":56,"keywords":63,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":4},"100485768","phase-1-minocycline-in-neurocognitive-outcomes---sickle-cell-disease-100485768","NCT05605366","Minocycline In Neurocognitive Outcomes - Sickle Cell Disease","MINO-SCD","Inclusion Criteria:\n\nAdults (age ≥ 18 years old) with SCD (HbSS and HbS-β0thalassemia genotypes only) who are followed at the University of Cincinnati Medical Center's SCD clinic are eligible to participate. As hydroxyurea is the standard-of-care in SCD, individuals on hydroxyurea will be included\n\nExclusion Criteria:\n\n1. adults with other SCD genotypes (HbSC or HbS- β+thalassemia),\n2. individuals with a history of overt stroke or other known neurological disorder,\n3. premature birth before 30 weeks gestation,\n4. monthly therapy with chronic blood transfusions,\n5. coexisting autoimmune condition due to an elevated risk for autoimmune-related complications with tetracyclines,\n6. tetracycline allergy.\n7. Women who are pregnant or breast-feeding",{"count":52,"type":20},30,[54],"PHASE1","Sickle cell disease (SCD) is a common, inherited blood disorder that primarily affects people of African Ancestry. It has a lot of complications including neurological complications. The neurological complications of SCD are particularly devastating and lead to cognitive decline even in the absence of overt brain injury. In such cases, it is thought that inflammation in the brain maybe partly responsible for the cognitive decline.\n\nThe main reasons for this research study are to see 1) how safe and 2) how well minocycline works to try to stop\u002Freverse cognitive decline in people with SCD. People with SCD are at risk for changes in their brain over time that can cause problems with learning, memory, and attention. Part of the reason for this is inflammation within the brain. Minocycline may be able to stop these brain changes by stopping this brain inflammation.\n\nMinocycline is a second-generation tetracycline antibiotic that has been shown to both inhibit neuroinflammation and improve cognitive function in a variety of neurodegenerative and psychiatric disorders but has not yet been studied in SCD. We are proposing here, a pilot double-blinded, randomized controlled trial to examine the tolerability and early efficacy of minocycline in adults with SCD at two dosing regimens (200 mg and 300 mg daily) versus placebo over one year. Participants will undergo a neuropsychological exam using the NIH Toolbox Cognition Battery at both study enrollment and exit (after one year) to assess for changes\u002Fstability of cognition. Participants will receive monthly phone calls\u002Ftext messages to assess for adverse events and will be seen every three months for pill counts and routine laboratory monitoring. The primary outcome will be a comparison of adverse events across the two dosing strategies versus placebo. Early evidence for cognitive benefit will also be assessed from the results of the NIH Toolbox.",[57,58,59,60,61,29,62],"Sickle Cell Disease","Cognitive Impairment","Cognitive Decline","Cognitive Change","Cognitive Dysfunction","Neuroinflammatory Response",[64,65,66,67],"sickle cell disease","benign hematology","cognitive dysfunction","neuroinflammation","NOT_YET_RECRUITING","2026-05-11",{"date":71,"type":35},"2026-05-14",{"date":73,"type":20},"2026-12-01",{"date":75,"type":20},"2028-06-15",{"name":77,"class":42},"University of Cincinnati",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":15,"sex":16,"minAge":86,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":21,"phases":88,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":43},"100288561","patient-centered-neurorehabilitation-pcn-100288561","NCT03036319","Patient-Centered NeuroRehabilitation (PCN)","Patient-Centered NeuroRehabilitation","PCN","Inclusion Criteria:\n\n1. Individuals who have reported cognitive dysfunction and cognitively intact participants.\n2. Participants will be age 50 or older\n\nExclusion Criteria:\n\n1. A history of epilepsy\n2. Sensory or motor impairments that limit the ability to take part in the study\n3. Current alcohol or drug abuse\u002Fdependence\n4. Those who are currently pregnant or may become pregnant during the duration of the study (if there is a question of pregnancy, pregnancy tests will be available for participants at no charge)\n\nThose who are being evaluated for TES methodology will also be excluded for 1) metallic or electronic implant 2) skull plates or other cranial implants that affect TES","50 Years",{"count":19,"type":20},[23],"As individuals grow older, a number of factors can reduce our cognitive (or thinking) abilities such as \"normal\" aging, neurodegenerative diseases, and cardiovascular disease. This study will evaluate whether cognitive rehabilitation and transcranial electrical stimulation (TES) can improve cognitive abilities. Cognitive rehabilitation refers to methods that are used to improve tasks people have trouble doing in everyday life. Transcranial electrical stimulation uses small amounts of electricity to try to alter brain functioning. These approaches may help improve cognitive abilities like attention, learning, memory, finding words, and problem solving as well as everyday functioning. The goal of this study is to identify how to best use these methods, either alone or in combination.",[29],"2026-01-12",{"date":93,"type":35},"2026-01-14",{"date":95,"type":4},"2016-06",{"date":97,"type":20},"2027-11",{"name":99,"class":42},"University of Michigan",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":21,"phases":109,"briefSummary":110,"conditions":111,"keywords":115,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":43},"100579117","isolated-versus-combined-cognitive-and-motor-high-tech-rehabilitation-100579117","NCT06820125","Isolated Versus Combined Cognitive and Motor High-tech Rehabilitation","Isolated Versus Combined Cognitive and Motor High-tech Rehabilitation in Patients with Multiple Sclerosis","Inclusion Criteria:\n\n* presence of mild (one or two neuropsychological tests below the cut-off score, 5th percentile) or severe (more than two neuropsychological tests below the cut-off score, 5th percentile) cognitive impairment,\n* mild to moderate walking disability with Expanded Disability Status Scale (EDSS) between 3 and 6,\n* no relapse or associated steroid use in the past three months,\n* adequate visual and auditory capacity to operate computer software.\n\nExclusion Criteria:\n\n* presence of other neurological disorders than MS,\n* major psychiatric disorders,\n* high levels of anxiety and\u002For depression (score\\>20 for Depression scale and up to 14 for Anxiety scale on Italian adaptation of the Depression, Anxiety and Stress Scale (DASS-21),\n* substance abuse,\n* any type of rehabilitation intervention in the month prior to recruitment\n* pharmacological therapy not well defined and\u002For changed during the study\n* presence of paroxysmal vertigo\n* lower limb botulinum toxin injections within the previous 12 weeks",{"count":108,"type":20},48,[23],"The first aim of this project is to investigate the effects of different high-tech neurorehabilitation interventions (cognitive, motor, and combined cognitive-motor) on both cognitive and motor disability outcomes in people with multiple sclerosis (MS).\n\nThe second aim is to identify the cognitive and motor profiles of MS patients who benefit the most from either the combined cognitive-motor rehabilitation intervention or the isolated cognitive or motor treatments.",[112,113,29,114],"Rehabilitation","Multiple Sclerosis","Motor Deficits",[116,117,118,119],"rehabilitation","multiple sclerosis","cognitive deficits","motor deficits","2025-02-05",{"date":122,"type":35},"2025-02-11",{"date":124,"type":35},"2023-07-05",{"date":126,"type":20},"2026-07-05",{"name":128,"class":42},"Universita di Verona",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":21,"phases":139,"briefSummary":140,"conditions":141,"keywords":152,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":43},"100420789","neurorehabilitation-through-hippotherapy-of-a-brain-stroke-100420789","NCT04759326","Neurorehabilitation Through Hippotherapy of a Brain Stroke","Neurorehabilitation Through Hippotherapy on Neurofunctional Sequels of Brain Stroke: (i) Effect on Patient's Functional Independence, Sensorimotor and Cognitive Capacities and Quality of Life (ii) Effect on Caregivers' Quality of Life","HippoPostCVA","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Ischemic or haemorrhagic stroke according to ICD 10 I61-I69 (30)\n* Inclusion \\> 3 months post-stroke\n* Deficit still existing (Rankin score ≥ 3 and ≤ 4 at inclusion)\n* Existing declaration of informed consent\n* Affiliation of the patient to a social security scheme\n* Minimal abduction of the hip of 25 degrees bilateral with no history of hip dislocation and\u002For dysplasia\n* Certificate of non-contraindication issued by the referring physician\n\nExclusion Criteria:\n\n* Major cognitive impairment affecting comprehension (Mini Mental State Examination test \\\u003C 24 points)\n* Global or sensory aphasia\n* Neurological or psychiatric co-morbidity (other than mild-to-moderate post-stroke depression)\n* Evidence of an uncontrolled seizure disorder\n* Substance abuse\n* History of uncontrolled pain\n* History of allergic reactions to dust and\u002For horsehair, or severe asthma\n* Overweight (≥ 110 kg)\n* Contraindications to physical activity\n* Inability or medical contraindication to travel to the Equiphoria Institute by personal car or taxi\n* History of horse riding or hippotherapy care during the last 6 months\n* Pregnant or lactating women\n* Patients participating in other biomedical research or in a period of exclusion",{"count":138,"type":20},52,[23],"Cerebrovascular accident \\[CVA\\] (medical term for stroke) is a high burden worldwide disorder and the second leading cause of disability. As illustrated by the number of survivors that remain disabled after a CVA (2 out of 3 according to the US National Stroke Association), recovery is limited, and novel neurorehabilitation approaches are urgently needed. Hippotherapy is an emerging specialized rehabilitation approach, performed by accredited health professionals on a specially trained horse via its movement. A body of scientific evidence has gradually emerged in recent years, showing robust benefits of hippotherapy in various massive neurological disabling conditions including brain stroke.\n\nThe aim of the study is to analyze the effect of a hippotherapy program of several cycles delivered during 22 weeks in total, on the functional and global evolution of post-stroke patients (with a score of Rankin ≥ 3 at inclusion) during the outpatient rehabilitation phase. A second purpose is to measure the impact of the intervention on the quality of life of their close caregivers.\n\nA prospective clinical trial on the effectiveness of hippotherapy versus conventional outpatient rehabilitation alone will be carried out. The 22-weeks program includes three cycles of hippotherapy as follows: an initial 2-weeks cycle, an intermediate 1-week cycle and a final 1-week cycle. One-hour daily sessions will be conducted during each cycle exclusive additional rehabilitation care. After each cycle, the patients will have a 9-weeks rest period where they will continue their conventional therapy. A battery of clinical tests will measure both functional and psychological outcome. The primary end point will be the functional independence of the patient. The secondary end points will consider the patient's sensorimotor and cognitive function, the severity of stroke and the quality of life, as well as the caregivers' burden and quality of life.\n\nProgram evaluation is important in neurorehabilitation to ensure that patients are achieving meaningful outcomes from the care. A primary question is how do stroke patients clinically evolve after being discharged from the hospital and how stable is the achieved rehabilitation outcome. Hippotherapy optimizes brain plasticity and has a strong impact on the global rehabilitation process and functional outcome of these patients. A remaining question concerns the improvement of the caregivers' quality of life.",[142,143,144,145,146,147,29,148,149,150,151],"Cerebrovascular Accident","Neurorehabilitation","Neuroplasticity","Hippotherapy","Silent Neurofunctional Barriers","Functional Deficit","Psychological Trauma","Autonomy","Quality of Life","Caregiver Burnout",[153,154,155],"NeuroRehabilitation through hippotherapy","Brain plasticity","Functional recovery","2024-07-30",{"date":158,"type":35},"2024-07-31",{"date":160,"type":35},"2022-04-27",{"date":162,"type":20},"2026-03",{"name":164,"class":42},"Alliance Equiphoria",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":175,"phases":4,"briefSummary":176,"conditions":177,"keywords":181,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":192},"100537492","validation-of-the-lithuanian-version-of-the-bnss-cdss-and-the-scors-100537492","NCT06278532","Validation of the Lithuanian Version of the BNSS, CDSS, and the SCoRS","Validation of the Lithuanian Version of the Brief Negative Symptoms Scale, Calgary Depression Scale for Schizophrenia, and the Schizophrenia Cognition Rating Scale","Inclusion Criteria:\n\n* age 18 - 65 years old;\n* Diagnosis of F20, F25 or F21 according to ICD-10;\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* Age younger than 18 or older than 65 years old;\n* Did not sign the informed consent form;\n* Legally inactive person\n* Patients with a comorbid or primary diagnosis of mental retardation according to ICD-10 (F70 - F79);\n* Patients with a comorbid or primary diagnosis of mental and behavioural disorders due to psychoactive substance use (F10 - F19)\n* Patients with a comorbid of primary diagnosis of organic, including symptomatic, mental disorders (F00 - F09)","65 Years",{"count":174,"type":20},200,"OBSERVATIONAL","This study aims to validate the Lithuanian version of the Brief Negative Symptoms Scale, Calgary Depression Scale for Schizophrenia, and Schizophrenia Cognition Rating Scale in a Lithuanian sample. This will be done by comparing results obtained from the Brief Negative Symptoms Scale, Calgary Depression Scale for Schizophrenia, and Schizophrenia Cognition Rating Scale with results obtained from the Positive and Negative Symptoms Scale, the Montgomery Asberg Depression Rating Scale, and the Montreal Cognitive Assessment test.",[178,179,180,29],"Schizophrenia","Negative Symptoms in Schizophrenia","Depressive Symptoms Due to Primary Psychotic Disorder (Diagnosis)",[182],"Schizophrenia, Negative symptoms, Depressive symptoms of Schizophrenia, Cognitive deficits of Schizophrenia","2024-02-19",{"date":185,"type":35},"2024-02-26",{"date":187,"type":35},"2023-12-11",{"date":189,"type":20},"2026-12-11",{"name":191,"class":42},"Lithuanian University of Health Sciences",2]